Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × atezolizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 106 Carcinoma, Hepatocellular 61 Breast Neoplasms 44 Neoplasms 41 Small Cell Lung Carcinoma 40 Triple Negative Breast Neoplasms 36 Lung Neoplasms 34 Colorectal Neoplasms 34 Melanoma 31 Urinary Bladder Neoplasms 29 Carcinoma, Transitional Cell 29 Neoplasm Metastasis 28 Carcinoma, Renal Cell 23 Ovarian Neoplasms 19 Stomach Neoplasms 15 Head and Neck Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Uterine Cervical Neoplasms 13 Prostatic Neoplasms 11 Liver Neoplasms 11 Recurrence 10 Solid Tumors 9 Lymphoma 9 Glioblastoma 9 Sarcoma 8 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Mesothelioma, Malignant 7 Endometrial Neoplasms 7 Carcinoma, Merkel Cell 7

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡